

CURRICULUM VITAE

PART I: GENERAL INFORMATION

Date Prepared: January 24, 2022

Name Karen S. Anderson, M.D., Ph.D.

Office Address: Biodesign Institute
School of Life Sciences
Arizona State University
PO Box 876401
Tempe AZ 85287-6401

Email Karen.Anderson.1@asu.edu
Tel 480-965-6982

Education:

1986 B.A. Department of Chemistry
University of Virginia, Charlottesville, VA

1994 M.D. Duke University School of Medicine
Medical Scientist Training Program

1994 Ph.D. Department of Microbiology and Immunology
Duke University, Durham NC
Advisor: Dr. Peter Cresswell
Thesis: Assembly and Intracellular Transport of MHC Glycoproteins

Internship and Residency

1994-1995 Intern, Department of Internal Medicine
Brigham and Women's Hospital
75 Francis St, Boston MA 02115

1995-1997 Resident, Department of Internal Medicine
Brigham and Women's Hospital
75 Francis St, Boston MA 02115

Clinical Fellowship

1997-2000 Clinical Fellow, Adult Hematology and Oncology
Dana Farber Cancer Institute
44 Binney St, Boston, MA 02115

Licensure and Certification

1996-present Registered Physician, Massachusetts Board of Medicine
1997-2007 Board Certified, American Board of Internal Medicine
2000-present Board Certified, Medical Oncology
2001-2011 Board Certified, Hematology
2012-present Registered Physician, Arizona Board of Medicine

Academic Appointments

2000-2011 Instructor in Medicine
Harvard Medical School
Dana Farber Cancer Institute
44 Binney St, Boston MA 02115

2011-2017	Associate Professor Biodesign Institute School of Life Sciences Arizona State University
2013-present	Associate Professor of Medicine Mayo Clinic Arizona
2017-present	Professor Biodesign Institute School of Life Sciences Arizona State University PO Box 876401, Tempe AZ 85287-6401
2020-present	Associate Dean of Strategic Research The College of Liberal Arts and Sciences Arizona State University

Professional Societies

1999-present	American Association for Cancer Research, Member
2001-present	American Society of Clinical Oncology, Member
2002-2008	American Society of Hematology, Member

Awards and Honors

2015	AZ Business Magazine – Most Influential Women in Arizona
2015	Phoenix Business Journal- Health Care Heroes Award: Physician
2015	Certificate of Special Congressional Recognition, U.S.
2020	Outstanding Faculty Mentor, ASU Faculty Women’s Association

PART III: BIBLIOGRAPHY

Original Research Articles

1. Pearson WR, Reinhart J, Sisk SC, **Anderson KS**, and Adler PN. Tissue-specific induction of murine glutathione transferase mRNAs by butylated hydroxyanisole. *J. Biol. Chem.* 1988 Sep 15; 263(26):13324-32, PMID: 3417659.
2. Cerundulo V, Alexander J, **Anderson KS**, Lamb C, Cresswell P, McMichael A, Gotch, F, and Townsend A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. *Nature.* 1990 May 31;345(6274):449-52. PMID 2342577.
3. **Anderson KS**, Cresswell P, Gammon M, Hermes J, Williamson A, and Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. *J. Exp. Med.* 1991 Aug 1;174(2):489-92. PMID: 1856631. PMCID: PMC2118909.
4. Click EM, **Anderson KS**, Androlewicz MJ, Wei ML, and Cresswell P. Transport and expression of class I MHC glycoproteins in an antigen-processing mutant cell line. *Cold Spring Harb Symp. Quant. Biol.* 1992; 57:571-7. PMID: 1339695.
5. **Anderson KS**, Alexander J, Wei M, and Cresswell P. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. *J. Immunol.* 1993 Oct 1;151(7):3407-19. PMID: 8376783.

6. Androlewicz M, **Anderson KS**, and Cresswell P. Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manor. Proc. Natl. Acad. Sci. USA 1993 Oct 1;90(19):9130-4. PMID: 8415666. PMCID: PMC47515.
7. **Anderson KS**, and Cresswell P. A role for calnexin (IP90) in the assembly of class II MHC molecules. EMBO 1994 Feb 1;13(3):675-82. PMID: 8313912. PMCID: PMC394858.
8. Schultze JL, Maecker B, von Bergwelt-Baildon MS, **Anderson KS**, Vonderheide RH. Tumor immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang. 2001 Feb; 80(2):81-9. PMID: 11378969
9. Vonderheide RH, **Anderson KS**, Hahn WC, Butler MO, Schultze JL, Nadler LM. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res. 2001 Nov; 7(11):3343-8. PMID: 11705846.
10. Vonderheide RH, Schultze JL, **Anderson KS**, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpennig KW, Hahn WC, Nadler LM. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res. 2001 Dec 1;61(23):8366-70. PMID: 11731409.
11. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, **Anderson KS**, Wucherpennig KW, Nadler LM, and Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen presenting cells: potential for clinical application. Blood. 2002 May 1;99(9):3319-25. PMID: 11964299.
12. Maecker B, **Anderson KS**, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, and Schultze JL. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. British J. Haematology, 2003 Jun;121(6):842-8. PMID: 12786794.
13. Maecker B, Sherr DH, Vonderheide RH, Von Bergwelt-Baildon MS, Hirano N, **Anderson KS**, Xia Z, Butler MO, Wucherpennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood: 2003 Nov 1;102(9):3287-94. PMID: 12869499.
14. Vonderheide, RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen D-Y, Stephans KF, Masutomi K, Loda M, Xia Z, **Anderson KS**, Hahn WC, and Nadler LM. Vaccination of cancer patients against telomerase induces functional anti-tumor CD8+ T lymphocytes. Clin. Cancer Res. 2004 Feb. 1;10(3): 828-39. PMID: 14871958.
15. Weihsrauch MR, Ansén S, Jurkeiwicz E, Geisen C, Xia Z, **Anderson KS**, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, and Nadler LM. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 2005. Aug 15;11(16):5993-6001. PMID: 16115944.
16. Maecker B, Von Bergwelt-Baildon MS, **Anderson KS**, Vonderheide RH, Anderson KC, Nadler LM, and Schultze JL. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin Exp Immunol. 2005 Sep;141(3):558-62. PMID: 16045747. PMCID: PMC1809449.
17. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, **Anderson KS**, Harris LN,

- Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K. Molecular definition of breast tumor heterogeneity. *Cancer Cell* 2007 Mar;11(3): 259-73. PMID: 17349583.
18. **Anderson KS**, Ramachandran N, Wong J, Raphael JV, Hainsworth E, Demirkan G, Cramer D, Aronzon D, Hodi FS, Harris L, Logvinenko T, Labaer J. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. *J Proteome Res.* 2008 Apr; 7(4):1490-1499. PMID: 18311903. PMCID: PMC3640352. doi: 10.1021/pr700804c.
 19. *Ramachandran N, ***Anderson KS**, Raphael JV, Hainsworth E, Sibani S, Montor W, Pacek M, Wong J, Eljanne M, Sanda MG, Hu Y, Logvinenko T, and Labaer J. Tracking humoral responses using self assembling protein microarrays. *Proteomics Clin. Appl.* 2008 Oct;2(10-11): 1518-27 (*=co-first authors) PMID: 21136799. PMCID: PMC3158030. doi: 10.1002/prca.200800034.
 20. **Anderson KS**, Wong, J, Polyak K, Aronzon D, and Enerbäck, C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. *Br J Dermatol.* 2009; Feb;160(2):325-32. PMID: 19016707. doi: 10.1111/j.1365-2133.2008.08904.
 21. Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, **Anderson KS**, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. *Vaccine.* 2009 Mar 13;27(12):1825-33. PMID: 19201387. doi: 10.1016/j.vaccine.2009.01.089.Epub 2009
 22. Wong J, Sibani S, Lokko NL, LaBaer J, and **Anderson KS**. Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. *J Immunol Methods* 2009, Oct 31;350(1-2):171-82. PMID: 19732778. PMCID: PMC2974181. doi: 10.1016/j.jim.2009.08.013.
 23. **Anderson KS**, Wong J, Vitonis A, Crum CP, Sluss PM, LaBaer J, and Cramer D. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. *Cancer Epidemiol Biomarkers Prev.* 2010 Mar;19(3):859-68. PMID: 20200435. PMCID: PMC2838192. doi: 10.1158/1055-9965.
 24. Reimer A, Keskin D, Zhang G, Handley M, **Anderson KS**, Brusic V, Reinhold B, and Reinherz E. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. *J.Biol.Chem.* 2010. Sep 17;285(38):29608-22. PMID: 20615877. PMCID: PMC29237992. doi: 10.1074/jbc.M110.126722.
 25. **Anderson KS**, Petersson S, Wong J, Shubbar E, Lokko NN, Carlström M and Enerback C. Elevation of serum epidermal growth factor and IL-1 receptor antagonist in active psoriasis vulgaris. *Br J Dermatol.* 2010 Nov;163(5):1085-9. PMID: 20716221. doi: 10.1111/j.1365-2133.2010.09990.x.
 26. **Anderson KS**, Sibani S, Wallstrom G, Qiu J, Mendoza E, Raphael J, Hainsworth E, Montor WR, Wong J, Park JG, Lokko N, Logvinenko T, Ramachandran N, Godwin AK, Marks J, Engstrom P, and LaBaer J. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. *J. Proteome Res.* 2011 Jan 7;10(1):85-96. PMID 20977275. PMCID: PMC3158028. doi: 10.1021/pr100686b.
 27. Yang C, Hayashida T, Forster N, Li C, Shen D, Maheswari S, Chen L, **Anderson KS**, Sgroi D and Schmidt EV. The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. *Cancer Research* 2011, Feb 1;71(3):937-45. PMID: 21127199. PMCID: PMC3074111. doi: 10.1158/0008-5472.CAN-10-1471.
 28. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, **Anderson KS**, Liu Q, Ewen ME, Yao X, and Song E. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. *Cancer Cell*, 2011 Apr 12;19(4):541-55. PMID: 21481794. PMCID: PMC3107500. doi: 10.1016/j.ccr.2011.02.006.

29. **Anderson KS**, Zeng W, Sasada T, Choi J, Riemer AB, Su M, Drakoulakos D, Kang YJ, Brusica V, Wu C, and Reinherz EL. Impaired tumor antigen processing by immunoproteasomes in CD40-activated B cells and dendritic cells. *Cancer Immunol. Immunother.* 2011, Jun;60:857-67. PMID: 21400024. PMCID: PMC3547125. doi: 10.1007/s00262-011-0995-5.
30. **Anderson KS**, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai S, Longtine J, McClean M, LaBaer J, Kelsey KT, and Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. *Br. J. Cancer* 2011 June 7;104(12): 1896-905. PMID: 21654689. PMCID: PMC3111202. doi:10.1038/bjc.2011.171
31. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, **Anderson KS**, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. *J Clin Invest.* 2011 Jul; 121(7):2723-35. PMID:21633165. PMCID:3223826. doi:10.1172/JCI44745.
32. **Anderson, KS**. Multiplexed detection of antibodies using programmable bead arrays. *Methods Mol. Biol.* 2011, 723:227-38. PMID: 21370069. PMCID: PMC3432636. doi: 10.1007/978-1-61779-043-0_15.
33. Wallstrom G, **Anderson KS**, LaBaer J. Biomarker discovery for heterogeneous diseases. *Cancer Epidemiol Biomarkers Prev.* 2013 May;22(5):747-755. doi: 10.1158/1055-9965.EPI-12-1236. Epub 2013 Mar 5. PMID: 23462916.
34. Wang J, Barker K, Steel J, Park J, Saul J, Festa F, Wallstrom G, Yu X, Bian X, **Anderson KS**, Figueroa JD, Labaer J, Qiu J. A versatile protein microarray platform enabling antibody profiling against denatured proteins. *Proteomics Clin Appl.* 2013 June;7(5-6):378-83. PMID: 23027520. doi: 10.1002/prca.201200062
35. Zeng W, Su M, **Anderson KS**, Sasada T. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens. *Immunobiology.* 2014 Aug;219(8):583-92. doi: 10.1016/j.imbio.2014.03.003. Epub 2014 Mar 20. PMID: 24713579
36. D'Souza G, Gross ND, Pai SI, Haddad R, **Anderson KS**, Rajan S, Gerber J, Gillison ML, Posner MR. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. *Journal of Clinical Oncology.* 2014 Aug 10;32(23):2408-15. doi:10.1200/JCO.2014.55.1341 Epub 2014 Apr 28. PMID: 24778397
37. **Anderson KS**, Cramer DW, Sibani S, Wallstrom G, Wong J, Park J, Qiu J, Vitonis A, LaBaer J. Autoantibody signature for the serologic detection of ovarian cancer. *Journal Proteome Research.* 2015 Jan 2;14(1):578-86 doi: 10.1021/pr500908n. Epub 2014 Nov 17. PMID 25365139; PMCID: PMC4334299
38. Marks JR, **Anderson KS**, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. *Cancer Epidemiol Biomarkers Prev.* 2015 Feb;24(2):435-41. doi: 10.1158/1055-9965.EPI-14-1178. Epub 2014 Dec 3. PMID: 25471344 PMCID: PMC4323938
39. Chowell D, Castillo-Chavez C, Krishna S, Qiu X, **Anderson KS**. Modelling the effect of early detection of Ebola. *Lancet Infect Dis.* 2015 Feb;15(2):148-49. doi: 10.1016/S1473-3099(14)71084-9. Epub 2015 Jan 19. PMID: 25749063
40. Chowell D, Krishna S, Becker PD, Cocita, C, Shu J, Tan X, Greenberg PD, Klavinskis LS, Blattman JN, **Anderson KS**. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8⁺ T cell

epitopes. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):E1754-62. doi: 10.1073/pnas.1500973112. Epub 2015 Mar 23. PMID: 25831525; PMCID: PMC4394253

41. **Anderson KS**, Dahlstrom KR, Cheng JN, Alam R, Li G, Wei Q, Gross ND, Chowell D, Posner M, Sturgis EM. HPV 16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. *Oral Oncol.* 2015 Jul;51(7):662-7. doi: 10.1016/j.oraloncology.2015.04.011. Epub 2015 May 6. PMID: 25957822; PMCID: PMC4457560
42. Chang JM, McCullough AE, Dueck AC, Kosiorek HE, Ocal IT, Lidner TK, Gray RJ, Wasif N, Northfelt DW, **Anderson KS**, Pockaj BA. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma. *Ann Surg Oncol.* 2015 Dec;22 Suppl 3:509-15. doi: 10.1245/s10434-015-4616-y. Epub 2015 May 22. PMID: 26001860
43. Wang J, Figueroa JD, Wallstrom G, Barker K, Park JG, Demirkan G, Lissowska J, **Anderson KS**, Qiu J, LaBaer J. Plasma Autoantibodies Associated with Basal-like Breast Cancers. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep;24(9):1332-40. doi: 10.1158/1055-9965.EPI-15-0047. Epub 2015 Jun12. PMID: 26070530
44. Dahlstrom KR, **Anderson KS**, Cheng JN, Chowell D, Li G, Posner M, Sturgis EM. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. *Clin Cancer Res.* 2015 Jun 15;21(12):2861-9. doi: 10.1158/1078-0432.CCR-14-3323. PMID: 26078432
45. **Anderson KS**, Gerber JE, D'Souza G, Pai SI, Cheng JN, Alam R, Kesiraju S, Chowell D, Gross ND, Haddad R, Gillison ML, Posner M. Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. *Oral Oncol.* 2015 Aug;51(8):751-8. doi: 10.1016/j.oraloncology.2015.05.007. Epub 2015 Jun 18. PMID: 26094591
46. Barrett MT, **Anderson KS**, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. *Oncotarget* 2015 Sep 22;6(28):26483-93. doi: 10.18632/oncotarget.4494 PMID: 26317899
47. Linnaus ME, Dueck AC, Kosiorek HE, Gray RJ, Wasif N, Northfelt DW, **Anderson KS**, McCullough AE, Wong WW, Halyard MY, Patel SH, Pockaj BA. Regional recurrence in the era of sentinel lymph node biopsy. *Am J Surg.* 2015 Dec;210(6):1155-61. doi:10.1016/j.amjsurg.2015.09.001. Epub 2015 Sep 28. PMID: 26601646
48. Smith JT, Katchman BA, Kullman DE, Obahiagbon U, Lee YK, O'Brien BP, Raupp GB, **Anderson KS**, Blain Christen J. Application of Flexible OLED Display Technology to Point-of-Care Medical Diagnostic Testing. *IEEE/OSA Journal of Display Technology.* Sep 2015
49. Ewaisha R, Meshay I, Resnik J, Katchman BA, and **Anderson KS**. Programmable protein arrays for immunoprofiling HPV-associated cancers, *Proteomics.* 2016 Apr;16(8):1215-24. doi: 10.1002/pmic.201500376. Epub 2016 Apr 7. PMID: 27089055
50. Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, **Anderson KS**. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. *Proteomics Clin Appl.* 2016 Jul;10(7):720-31. doi: 10.1002/prca.201500096. Epub 2016 May 17. PMID: 27121307
51. Katchman BA, Smith JT, Obahiagbon U, Kesiraju S, Lee YK, O'Brien B, Kaftanoglu K, Blain Christen J, **Anderson KS**. Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. *Sci Rep.* 2016 Jul 4;6:29057. doi: 10.1038/srep29057. PMID: 27374875

: Senior

52. Dahlstrom KR, **Anderson KS**, Sturgis EM. Human Papillomavirus-Associated Oropharyngeal Cancer: Not Just White Men Anymore. *JAMA Oncol.* 2016 Dec 8. doi:10.1001/jamaoncol.2016.3510 PMID: 27930755
53. Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, **Anderson KS**, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, m Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. *Clin Cancer Res.* 2017 Mar 7. PMID: 28270497
54. Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, **Anderson KS**. Autoantibody biomarkers for the detection of serous ovarian cancer. *Gynecol Oncol.* 2017 Apr 17. Pii: S0090-8258(17)30775-8 doi: 10.1016/j.yfyno.2017.04.005. PMID: 28427776
55. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, **Anderson KS**, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Couskos G. A phase 2, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. *Ann Oncol.* 2017 May 1. 28(5):996-1004. Doi: 10.1093/annonc/mdx049.
56. Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, **Anderson KS**, Schoenfeld JD. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. *Cancer Biomarker* 2017;19(2):129-136. PMID: 28387659
57. **Anderson KS**, Wallstrom G, Langseth H, Posner M, Cheng JN, Alam R, Chowell D, Furre IE, Mork J. Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. *Oral Oncology* 2017 Oct. 2017 Sep 1. PMID: 28939065
58. Chen M, Andrezzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, **Anderson KS**. Development and Validation of a Novel Clinical Fluorescence in Situ Hybridization Assay to Detect JAK2 and PD-L1 amplification. *Modern Pathology.* 2017 Nov;30(11):1516-1526.PMID: 28752839
59. Inan H, Wang S, Inci F, Baday M, Zangar R, Kesiraju S, **Anderson KS**, Cunningham BT, Demirci U. Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. *Sci Rep.* 2017 Jun 12;7(1):3322. PMID: 28607383
60. Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, **Anderson KS**, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the Evolutionary and Ecological Features of Neoplasms. *Nature Reviews Cancer.* 2017 Oct;17(10):605-619. PMID: 28912577
61. Chang JM, Kosiorek HE, Wasif N, Gray RJ, Stucky CH, Northfelt DW, **Anderson KS**, McCullough AE, Tolgay Ocal I, Pockaj BA. Discussion of: "The success of sentinel lymph node biopsy after neoadjuvant therapy: A single institution review". *Am J Surg.* 2017 Dec;214(6):1102-1103. PMID: 29037421
62. Ewaisha R, Panicker G, Maranian P, Unger R, **Anderson KS**. Serum Immune Profiling for Early Detection of Cervical Disease. *Theranostics.* 2017 Aug 23;7(16):3814-3823. PMID: 29109779
63. Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, **Anderson KS**, Fu L, Cole DEC, Le T, Wu X, Borges CR. Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β 1-4 Branching, β 1-6 Branching, and a2-6 Sialylation in Cancer. *J Proteome Res.* 2018 Jan 5;17(1):543-558. PMID: 29129073

64. Chowell D, Napier J, Gupta R, **Anderson KS**, Maley CC, Wilson Sayres MA. Modeling the subclonal evolution of cancer cell populations. *Cancer Res.* 2017 Nov 29. PMID: 29187407
65. Dahlstrom KR, **Anderson KS**, Field MS, Chowell D, Ning J, Li N, Wei Q, Li G, Sturgis EM. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. *Cancer.* 2017 Dec 15;123(24):4886-4894. PMID: 28898394
66. Obahiagbon U, Smith JT, Zhu M, Katchman BA, Arafa H, **Anderson KS**, Blain Christian JM. A Compact, Low-cost, Quantitative and Multiplexed Fluorescence Detection Platform for Point-of-Care Applications. *Biosensors and Bioelectronics.* 4 Apr 2018.
67. **Anderson KS**, Mork J, Langseth H, Wallstrom G. Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues. *Oral Oncol.* 2018 May. PMID: 29606498.
68. Kaaks R, Fortner RT, Hüsing A, Barrdahl M, Hopper M, Johnson T, Tjønneland A, Hansen L, Overvad K, Fournier A, Boutron-Ruault MC, Kvaskoff M, Dossus L, Johansson M, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Sieri S, Mattiello A, Palli D, Tumino R, Matullo G, Onland-Moret NC, Gram IT, Weiderpass E, Sánchez MJ, Navarro Sanchez C, Duell EJ, Ardanaz E, Larranaga N, Lundin E, Idahl A, Jirström K, Nodin B, Travis RC, Riboli E, Merritt M, Aune D, Terry K, Cramer DW, **Anderson KS**. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. *Int J Cancer,* 2018 Feb 22. PMID: 29473162
69. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. Krishna S, Ulrich P, Wilson E, Parikh F, Narang P, Yang S, Read AK, Kim-Schulze S, Park JG, Posner M, Wilson Sayres MA, Sikora A, **Anderson KS**. *Cancer Res.* 2018 Nov 1;78(21):6159-6170. PMID:30154146
70. Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers. Katchman BA, Zhu M, Blain Christen J, **Anderson KS**. *Proteomics Clin Appl.* 2018 Nov;12(6):e1800010. PMID: 29882373
71. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. MT Barrett, Elizabeth Lenkiewicz, Smriti Malasi, Anamika Basu, Jennifer Holmes Yearley, Lakshmanan Annamalai, Ann E. McCullough, Heidi E. Kosiorek, Pooja Narang, Melissa A. Wilson Sayres, Meixuan Chen, **Karen S. Anderson** & Barbara A. Pockaj. *Breast Cancer Research* 2018; 20 (1), 1-15
72. Chen M, Pockaj B, Andreozzi M, Barrett MT, Krishna S, Eaton S, Niu R, **Anderson KS**. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer. *Clin Breast Cancer.* 2018 Oct;18(5):e1205-e1215. Erratum in: *Clin Breast Cancer.* 2019 Feb;19(1):87-88. PMID:29933930
73. A Random Forest based approach to MHC class I epitope prediction and analysis. EA Wilson, S Krishna, **KS Anderson**. *The Journal of Immunology* 200 (1 Supplement), 2018; 99.11-99.11
74. Henderson MC, Silver MS, Tran Q, Letsios E, Mulpuri R, Reese DE, Lourenco AP, LaBaer J, **Anderson KS**, Hollingsworth A, Alpers J, Costantini C, Peterson H, Rohatgi N, Haythem A, Baker K, Northfelt D, Ghosh K, Grobmyer S, Polen W, Wolf J. A Non-Invasive Blood-Based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Post-Menopausal Women with BI-RADS 3, 4, or 5 Assessment. *Clin Cancer Res.* 2019 Jan 1;25(1):142-149. PMID:30185421
75. Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer. Hilal T, Mi L, Ertz-Archambault NM, Almquist DR, **Anderson KS**, Gray RJ, Pockaj BA, Northfelt DW. *Breast J.* 2019 Dec 26. PMID:31876083

76. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. Ertz-Archambault NM, Rogoff LB, Kosiorek HE, Ernst BJ, **Anderson KS**, Pockaj BA, Gray RJ, Northfelt DW. *Support Care Cancer*. 2019 Aug 11. PMID:31402403
77. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdignes N, Chin SF, Farooq M, Mejia R, Cronin PA, **Anderson KS**, Kosiorek HE, Northfelt DW, McCullough AE, Patel BK, Weitzel JN, Slavin TP, Caldas C, Pockaj BA, Murtaza M. *Sci Transl Med*. 2019 Aug 7;11(504). PMID: 31391323
78. The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study. Campos-Romero A, **Anderson KS**, Longatto-Filho A, Luna-Ruiz Esparza MA, Morán-Portela DJ, Castro-Menéndez JA, Moreno-Camacho JL, Calva-Espinosa DY, Acosta-Alfaro MA, Meynard-Mejía FA, Muñoz-Gaitán M, Alcántar-Fernández J. *Sci Rep*. 2019 Jul 12;9(1):10094. PMID: 31300693
79. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Ferdosi SR, Ewaisha R, Moghadam F, Krishna S, Park JG, Ebrahimkhani MR, Kiani S, **Anderson KS**. *Nat Commun*. 2019 Apr 23;10(1):1842. PMID:31015529
80. The neoepitope landscape of breast cancer: implications for immunotherapy. Narang P, Chen M, Sharma AA, **Anderson KS**, Wilson MA. *BMC Cancer*. 2019 Mar 4;19(1):200. PMID:30832597
81. MHC-TreASUre_Hunt: a computational pipeline for the identification of MHC-I peptides from mass spectrometry. EA Wilson, MA Wilson, **KS Anderson**. *MOLECULAR & CELLULAR PROTEOMICS* 2019; 18 (8), S74-S74.
82. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. BR McDonald, T Contente-Cuomo, SJ Sammut, A Odenheimer-Bergman, Anderson, KS. *Science translational medicine* 2019; 11 (504).
83. The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study. A Campos-Romero, **KS Anderson**, A Longatto-Filho, MALR Esparza, David J. Morán-Portela, Javier A. Castro-Menéndez, José L. Moreno-Camacho, Diana Y. Calva-Espinosa, Manuel A. Acosta-Alfaro, Freddy A. Meynard-Mejía, Marlene Muñoz-Gaitán & Jonathan Alcántar-Fernández. *Scientific reports* 2019; 9 (1), 1-10.
84. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. SR Ferdosi, R Ewaisha, F Moghadam, S Krishna, JG Park, Mo R. Ebrahimkhani, Samira Kiani & **Karen S. Anderson**. *Nature communications* 2019; 10 (1), 1-10
85. Autoantibodies in Early Detection of Breast Cancer. Rauf F, **Anderson KS**, LaBaer J. *Cancer Epidemiol Biomarkers Prev*. 2020 Dec;29(12):2475-2485.
86. Biomarkers and Strategies for Early Detection of Ovarian Cancer. Bast RC Jr, Lu Z, Han CY, Lu KH, **Anderson KS**, Drescher CW, Skates SJ. *Cancer Epidemiol Biomarkers Prev*. 2020 Dec;29(12):2504-2512.
87. Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer. Hilal T, Mi L, Ertz-Archambault NM, Almquist DR, **Anderson KS**, Gray RJ, Pockaj BA, Northfelt DW. *Breast J*. 2020 Jul;26(7):1449-1451.
88. Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. Phung TN, Lenkiewicz E, Malasi S, Sharma A, **Anderson KS**, Wilson MA, Pockaj BA, Barrett MT. *Sci Rep*. 2020 Jul 22;10(1):12190.

89. Resolving the Connection between Major Histocompatibility Complexes and Immune Outcomes using Unsupervised Clustering of Molecular Dynamics Simulations. EA Wilson, K Anderson, A Singharoy *Biophysical Journal* 118 (3), 452a.
90. Are we choosing wisely in elderly females with breast cancer? E Calderon, C Webb, HE Kosiorek, MDRJ Gray, P Cronin, K Anderson, Donald Northfelt, Ann McCullough Idris Tolgay Ocal, Barbara Pockaj. *The American Journal of Surgery* 218 (6), 1229-1233.
91. Proteomic and metabolomic approaches to biomarker discovery. HJ Issaq, TD Veenstra. Academic Press.
92. Total predicted MHC-I epitope load is inversely associated with mortality from SARS-CoV-2. Wilson EA, Hirniese G, Singharoy A, and **Anderson KS**. 2021, *Cell Reports Medicine*.
93. The Public Health Impact of Delaying a Second Dose of the BNT162b2 or mRNA-1273 COVID-19 Vaccine. Romero-Brufau S, Chopra A, Ryu AJ, Gel E, Raskar R, Kremers W, **Anderson KS**, Subramanian J, Krishnamurthy B, Abhishek S, Pasupathy K, Dong Y, O'Horo JC, Wilson WR, Mitchell O, Kingsley TC. *British Medical Journal*. 2021; *British Med J*.

Reviews, Chapters, and Editorials

1. Schultze JL, Maecker B, von Bergwelt-Baildon MS, **Anderson KS**, Vonderheide RH. Tumour immunotherapy: new tools, new treatment modalities, and new T-cell antigens. *Vox Sang*. 2001 Feb;80(2):81-9. Review. PMID: 11378969
2. Maecker B, von Bergwelt-Baildon MS, **Anderson KS**, Vonderheide RH, Schultze JL. Linking genomics to immunotherapy by reverse immunology-'immunomics' in the new millennium. *Curr Mol Med*. 2001 Nov;1(5):609-19. Review. PMID: 11899235
3. **Anderson KS**, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. *J Proteome Res*. 2005 Jul-Aug;4(4):1123-33. Review. PMID: 16083262
4. **Anderson KS**, Tumor vaccines for breast cancer. *Cancer Invest*. 2009 May;27(4):361-8. doi: 10.1080/07357900802574421. Review. PMID: 19358018
5. Tabernero MD, Lv L-L, **Anderson KS**. Autoantibody profiles as biomarkers of breast cancer. *Cancer Biomark*. 2010; 6(5-6):247-56. doi: 10.3233/CBM-2009-0139. Review. PMID: 20938085
6. Jaras K and **Anderson KS**. Autoantibodies in cancer: Prognostic biomarkers and immune activation. Solicited review, *Expert Rev. Proteomics*, *Expert Rev. Proteomics*, 2011 Oct;8(5):577-89.
7. Cole K, Tabernero M, **Anderson, KS**. Biologic characteristics of premalignant breast disease. *Translational Pathology of Early Cancer*, Editors Sudhir Srivastava and William Grizzle, 2011. *Cancer Biomark*. 2010;9(1-6):177-92. doi: 10.3233/CBM-2011-0187. PMID: 22112476
8. Qiu J, **Anderson KS**, *Proteomic and Metabolomic Approaches to Biomarker Discovery, Autoantibodies and Biomarker Discovery*, Editors Haleem Issaq and Tim Veenstra, 2012.
9. Suifi Neto J, Kho RM, Siufi DF, Baracat EC, **Anderson KS**, Abrão MS. Cellular, histologic and molecular changes associated with endometriosis and ovarian cancer. *J Minim Invasive Gynecol*. 2014 Jan-Feb;21(1):55-63. doi: 10.1016/j.jmig.2013.07.021. Epub 2013 Aug 17. Review PMID: 23962574
10. Katchman BA, Patriotis C, and **Anderson KS**. *Breast Cancer Biomarkers; Editor Sudhir Srivastava, Biomarkers in Cancer Screening and Early Detection*. Submitted.
11. Ernst B, **Anderson KS**. Immunotherapy for the treatment of breast cancer. *Current Oncology Reports* 2015 Feb;17(2):5. doi: 10.1007/s11912-014-1426-9 PMID: 25677118
12. Ewaisha R, Gawryltx CD, **Anderson KS**. Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. *Expert Rev Proteomics*. 2016 Feb; 13(2):201-11. doi:10.1586/14789450.2016.1132170. Epub 2016 Jan 4. PMID: 26653344
13. Ewaisha R, **Anderson KS**. Chapter title: Proteomic monitoring of B cell immunity. Book title: *Vaccine Design*, Editor: Sunil Thomas. Series Title: *Methods Mol Biol*. 2016;1403:131-52. Doi: 10.1007/978-1-4939-3387-7_6. PMID: 27076128
14. Krishna S, **Anderson KS**. T-cell epitope discovery for therapeutic cancer vaccines. *Vaccine Design*, Editor: Sunil Thomas. Series Title: *Methods Mol Biol*. 2016;1403:779-96. doi: 10.1007/978-1-4939-3387-7_45. PMID: 27076128

15. Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy. Wilson EA, **Anderson KS**. *Expert Rev Proteomics*. 2018 Dec;15(12):1065-1077. Review. PMID: 30408427
16. HPV: Immunology lessons from an ancient oncotarget. Krishna S, **Anderson KS**. *Oncotarget*. 2019 Feb 12;10(13):1269-1270. PMID:30863487
17. Weakly immunogenic CRISPR therapies. Wilson EA, **Anderson KS**. *Nat Biomed Eng*. 2019 Oct;3(10):761-762. PMID: 31591524

Thesis

Assembly and Intracellular Transport of MHC Glycoproteins

Thesis Advisor: Peter Cresswell PhD.

Department of Microbiology and Immunology, Duke University Medical Center. 1993

Proceedings of Meetings (past 15 years)

1. **Anderson, K.S**, Wucherpennig K.W., Haining W.N, Schultze J.L, Maecker B, Xia Z, Butler M.O, Vonderheide R.H, and Nadler LM. Potential of antigen-specific adoptive immunotherapy using peptide/mhc tetramers and microbeads for high-yield purification of cytotoxic T lymphocytes from peripheral blood. American Society of Hematology, San Francisco CA,2000.
2. **Anderson KS**, Urban, R., Ryan, D., Hedley, ML, Maecker, B., Beach, K., Nadler, LM. and Gribben, J. A Phase I DNA Vaccination Trial of Zyc300: Targeting the Tumor Antigen Cyp1B1. *Keystone, Tumor Immunology*, 2003.
3. **Anderson KS**, Richardson A., Jaklitsch M, Daley H., and Dranoff G. Preclinical Testing of an Autologous Breast Cancer Vaccine Engineered to Secrete GM-CSF. *DF/HCC Breast Cancer Research Symposium*, 2005
4. **Anderson KS**, Aronzon D, Keshaviah A, Keung E, Kamma M, Winer EP, Burstein HJ, Harris LN. Role of Host Immune Response Genes in the Clinical Response to Trastuzumab-Based Therapies. *San Antonio Breast Cancer Symposium*, 2006.
5. **Anderson KS**, Krop I, Wong J, Su M, Colson Y, Canning C, Winer E, and Dranoff G. A Phase I Study of an Autologous GM-CSF-Secreting Cancer Vaccine for Metastatic Breast Cancer. *NCI Spore Investigators' Meeting* 2007.
6. Barderas R, Ramachandran N, Hainsworth G, Wong J, Raphael J, Cramer D, LaBaer J, and **Anderson KS**. p53-specific autoantibodies target cryptic epitopes in the p53 core region in breast and ovarian cancer patient sera. *DF/HCC Breast Cancer symposium*, 2008.
7. Townes A, Drakoulakos D, Wong J, Gomez M, Miron P, Barderas R, LaBaer J, and **Anderson KS**. Identification of Her2-specific autoantibodies in early-stage Her2+ breast cancer patient sera. *DF/HCC Breast Cancer symposium*, 2008.
8. Barderas R, Ramachandran N, Hainsworth G, Wong J, Raphael J, Cramer D, LaBaer J, and **Anderson KS**. Distinct Patterns of Immunoreactivity from p53-specific autoantibodies in breast and ovarian cancer patient sera. *EDRN Scientific Workshop*, 2008.
9. **Anderson KS**, Ramachandran N, Wong J, Hainsworth G, Dranoff G, and LaBaer J. Immune Monitoring of Antibody Responses to Tumor Antigens Using Protein Microarrays: Application for Complex Immunotherapies. *ASCO* 2008.
10. **Anderson KS**, Sibani S, Hainsworth G, Raphael J, Logvinenko T, Ramachandran N, Sanda M, Engstrom P, Godwin A, Cramer D., and LaBaer J. Using Custom Protein Microarrays to Identify Autoantibody Biomarkers for the Early Detection of Cancer. *NCI Translational Research Working Group Meeting* 2008.
11. **Anderson KS**, Hodi FS, Sasada T, Canning C, Hassett M, Mayer E, Hannagan K, Wong J, Colson Y, Shoji B, Najita J, Sibani S, LaBaer J, Winer EP, and Dranoff G. A Phase I Study of an Autologous GM-CSF-Secreting Breast Cancer Vaccine. *San Antonio Breast Cancer Symposium* 2008.
12. **Anderson KS**, Sibani S, Wong J, Hainsworth G, Mendoza EA, Eugene R, Raphael J, Logvinenko T, Ramachandran N, Godwin A, Marks J, Engstrom P, and LaBaer J. Using Custom Protein Microarrays to Identify Autoantibody Biomarkers for the Early Detection of Breast Cancer. *San Antonio Breast Cancer Symposium* 2008.
13. Riemer AB, Keskin DB, Sasada T, **Anderson KS**, Reinherz EL. HPV-induced changes in antigen processing machinery components and MHC-class-I expression. *International Papillomavirus Conference*, 2009.
14. **Anderson KS**, Wong J, Crum C, Vitonis A, Sluss P, LaBaer J, and Cramer D. p53 Autoantibodies as

- potential detection and prognostic biomarkers in serous ovarian cancer. NCI/EDRN Scientific Workshop, 2009.
15. **Anderson KS**, Sasada T, Nelson EA, Khazaie K, Feng G, Lin S, and Frank DA. IL-6-mediated activation of STAT3 inhibits APC and T cell function in metastatic breast cancer. AACR 2010.
 16. **Anderson KS**, Wong J, Posner M, Riemer A, Lorch J, Haddad R, Bryan J, McLean M, and Kelsey K. Detection of Antibodies to the HPV16 Proteome in Head and Neck Cancer Patient Sera. ASCO 2010
 17. Riemer, AB, Keskin DB, Reinhold B, Zhang G, **Anderson KS**, Brusic V, and Reinherz EL. Mass spectrometry identifies a single dominant T cell epitope on HPV16-transformed HLA-A0201+ tumor cells. FOCIS 2010.
 18. DiJohnson DA, O'Rourke DJ, **Anderson KS**, and Liu BCS. Development of a whole proteome native antigen microarray platform to determine humoral responses to an experimental breast cancer vaccine. ASCO/NCI/EORTC Molecular Markers 2010.
 19. **Anderson KS**, Wong J, D'Souza G, Riemer AB, Lorch J, Haddad R, Pai S, Longtine J, Bryan J, McClean M, LaBaer J, Kelsey KT, Posner M. Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. AACR 2011.
 20. Gropper A, Burstein HJ, Harris L, **Anderson KS**, Gold JM, Younger WJ, Bunnell CA, Najita JS, Winer EP, and Mayer EL. Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ Breast cancer. ASCO 2011.
 21. Wallstrom G, **Anderson KS**, LaBaer J, HUPO, Implications of Disease Heterogeneity on Biomarker, Center for Personalized Diagnostics, Biodesign Institute, Arizona State University.
 22. Posner M, Wong J, D'souza G, Haddad R, **Anderson KS**. Changes in Serologic Levels of Antibodies to HPV 16 Proteins with Therapy Over Time: A Preliminary Assessment, Multidisciplinary Head and Neck Cancer Symposium - January 26-28, 2012, Arizona Biltmore, Phoenix.
 24. Wang J, Wallstrom G, Sampson J, Garcia E, **Anderson KS**, Yang R, Brinton L, Garcia-Closas M, Lissowska J, Sherman M, Figueroa J, Qiu J, LaBaer J. HUPO, Basal like Breast Cancer Autoantibody Profiling by Nucleic Acid Programmable Protein Array, 2012
 25. Unger ER, Panicker G, Wong J, Wallstrom G, Haddad R, D'Souza G, M Posner, and **KS Anderson**. Differential antibody responses to HPV16 in cervical and oropharyngeal cancer, Experimental Biology Meeting, Boston 2013.
 26. Amouzougan, E, **Anderson KS**. Phenotypic Characterization of Conditionally Reprogrammed Breast Cancer Cells, 2013 Annual Biomedical Research Conference for Minority Students.
 27. Siufi-Neto J, **Anderson KS**. Phenotype Characterization of conditionally reprogrammed cells of ovarian endometriosis, 12th World Congress on Endometriosis, 2014.
 28. McCullough A, Dueck A, Ocal I, Lidner T, Gray R, Wasif N, Northfelt D, **Anderson KS**, Pockaj B. Back to basics: Traditional Nottingham grade mitotic scores alone are significant in predicting survival. American Society of Breast Surgeons 15th Annual Meeting, 2014.
 29. **Anderson KS**, Designing Pipelines for Breast Cancer Biomarker Discovery and Validation, NCI NIH US-Japan Joint Workshop, Biomarkers for Early Cancer Detection. Feb 2014.
 30. Katchman B, °Alam R, Wallstrom G, LaBaer J, Hollingsworth MA, Cramer DW, **Anderson KS**, Identification of Autoantibody Biomarkers to Wild-Type and Mutant p53 in Pancreatic and Ovarian Cancer. AACR Apr 2014
 31. Pockaj B, McCullough A, Cunliffe G, **Anderson KS**, Alvarez L, Barrett M. Phosphatidylinositol 3-kinase (PI3-kinase) Pathway Aberrations are Frequently Seen in Triple Negative Breast Cancers, Society of Surgical Oncology 2014
 32. Nandakumar V, Ashcroft B, Davis G, Helland S, Han J, Li T, **Anderson KS**, Tran T, Fleisher D, Johnson RH, Bussey KJ, Meldrum DR, Quantifying three-dimensional cellular morphology and its heterogeneity in epithelial cancers by single-cell optical tomography, AACR 2014
 33. Wang J, Figueroa JD, Wallstrom G, Sampson J, Mendoza-Garcia E, Steel J, Park J, **Anderson KS**, Brinton L, Garcia-Closas M, Lissowska J, Sherman M, Qiu J, LaBaer J, Autoantibody biomarker discovery for basal-like breast cancers using nucleic acid programmable protein arrays, AACR 2014
 34. DeMichele A, Chen J, Chen L, Gray R, Donelson M, Komrokian S, Colameco C, Vaughn W, Tallman M, **Anderson KS**, Bromberg J. Associations between IL-6 genotype and IL-6 related tumor alterations in ER+ breast cancer: Results from ECOG2190/
 35. Chowell D, Krishna S, Blattman JN, **Anderson KS**. Hydrophobicity is a hallmark of immunogenic MHC class I T cell epitopes, Immunology AAI Annual Meeting, 2014
 36. Basu G, Ghazalpour A, Gatalica Z, **Anderson KS**, McCullough A, Spetzler D, Pockaj B. Expression of

- novel immunotherapeutic targets in triple negative breast cancer, ASCO, 2014
37. **Anderson KS**, Pepe M, Marks J, Engstrom P, Patriotis C, Zangar R, Skates S, Lampe P, LaBaer J, L C. A Blinded Multicenter Phase II Study of a Panel of Plasma Biomarkers for the Detection of Triple Negative Breast Cancer, SABCS 2014
 38. **Anderson KS**, Overmoyer B, Canning C, Hannagan K, Najita J, Wallstrom G, Winer EP, Dranoff G. A Phase Ib Study of an Adjuvant GM-CSF-Secreting Breast Cancer Vaccine, SABCS 2014
 39. Shah S, **Anderson KS**, Blain Christen J, Hasler J. Floating gate ISFET for therapeutic drug screening of breast cancer cells. IEEE International Symposium on Circuits and Systems. 2014:229-232.
 40. Peng K, **Anderson KS**, McCullough A, Reddy S, Basu G, Northfelt D, Andreozzi M, Barrett M, Pockaj B. PD-L1 Gene Amplification in Triple Negative Breast Cancer: Implications for Immunotherapy, SSO 2015
 41. °Mushtaq Z, Reyes Del Valle J, Cheng J, °Field M, **Anderson KS**. Expression of the measles virus proteome by RAPID ELISA for serological assays, AAAS 2015.
 42. Katchman B, °Alam R, °Field M, Viloría J, Wallstrom G, LaBaer J, Engstrom P, **Anderson KS**. A Protein Microarray Signature of Autoantibody Biomarkers for the Detection of HER2+ Breast Cancer, AACR 2015
 43. **Anderson KS**, Langseth H, Wallstrom G, Posner M, Cheng J, °Alam R, Chowell D, Mork J. Association of a Serum HPV 16 IgG Signature and Risk of Oropharyngeal Cancer, AACR 2015.
 44. **Anderson KS**, Klassen C, Dueck A, McCullough A, Northfelt D, Andreozzi M, Pockaj B, Barrett M. High-level amplification of chromosome 9p24 targeting PD-L1 and JAK2 correlates with worse DFS and OS in triple negative breast cancer, AACR 2015
 45. Skates S, **Anderson KS**, Liu T, Kulasingam V, Rabideau D, Wu C, Gillette M, Godwin A, Urban A, Marks J, Diamandis E, Zhang Z, Srivastava S, Kagan J, Patriotis C, Rodland K. Early detection research network (EDRN) validation of circulating ovarian cancer biomarkers, AACR 2015
 46. Chowell D, Krishna S, Snyder A, Makarov V, Chan TA, and **Anderson KS**. A predictive model to Identify immunogenic neoepitopes in patients with melanoma treated with CTLA-4 blockade, CRI-CIMT-EATI- AACR 2015 (Cancer Immunotherapy Conference).
 47. Krishna S, Nelson J, Parikh F, Kim-Schulze S, Posner M, Sikora A, **Anderson KS**. Discovering immunotherapeutic T-cell epitopes for HPV16-associated cancers, CRI-CIMT-EATI-AACR 2015
 48. Mishra R, °Alam R, Kinahan DJ, **Anderson KS**, Ducree J. Lipophilic-membrane based routing for centrifugal automation of heterogeneous immunoassays. IEEE International Conference on Micro Electro Mechanical Systems (MEMS). 2015;2015-February(February):523-526.
 94. Katchman BA, °Field MS, Wallstrom G, LaBaer J, Hollingsworth MA, **Anderson KS**. A Protein Microarray Signature of Autoantibody Biomarkers for the Detection of Pancreatic Adenocarcinoma. 30th Annual Aspen Cancer Conference. Apr 2015
 95. **Anderson KS**. Predicting T-Cell epitopes for immunology. Individualizing Medicine Conference, Mayo Rochester Sep 2015.
 96. Chen M, Andreozzi M, Gonzalez-Malerva L, Eaton S, Pockaj B, Barrett MT, **Anderson KS**. JAK2 copy number and targeted JAK2 inhibition of TNBC cell lines. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.
 97. **Anderson KS**, Andreozzi M, Pockaj BA, Hopper M, McCullough AE and Barrett MT. Amplification of chromosome 9p24 targeting PD-L1 and JAK2 correlates with altered tumor microenvironment expression profiles in triple negative breast cancer. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.
 98. Ferdosi SR, °Grewal H, Gonzalez-Malerva L, Eaton S, Briones N, LaBaer J and **Anderson KS**. Inhibition of breast cancers tumor cell lines by simvastatin is dependent on specific p53 mutation. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.
 99. Gawryletz C, **Anderson KS**, Cunliffe HE, Northfelt DW, McCullough AE, Lenkiewicz E, Malasi S, Pockaj BA, and Barrett MT. The genomic landscape of PD-L1, PD-L2, Jak2 (PDJ) amplified triple negative breast carcinoma. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.
 100. Ma CX, Gao F, Northfelt D, Goetz M, Forero A, Naughton M, Ademuyiwa F, Suresh R, **Anderson KS**, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Hoog J, Han J, Guo Z, Vij K, Santi S, Al-Kateb H, Mardis E, Ellis MJ. A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole in women with clinical stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.

101. Wang J, Figueroa JD, Wallstrom G, Barker K, Park JG, Demirkan G, Lissowska J, **Anderson KS**, Qiu J and LaBaer J. Plasma autoantibodies associated with basal-like breast cancers. San Antonio Breast Cancer Symposium (SABCS) Dec 2015.
102. Katchman BA, Smith JT, Blain-Christen J, and **Anderson KS**. Application of Flexible Display Technology to Low Cost Multiplexed Point-of-Care Medical Diagnostic Testing, Journal of Global Oncology.
103. Roesler AS, Krishna S, Qiu J, LaBaer J, **Anderson KS**. The APC capture: rapid identification of target CD8+ T cell epitopes by flow cytometry. Immunology Conference Seattle May 2016.
104. Krishna S, Parikh F, Nelson J, Clark A, Kim-Schulze S, Posner M, Sikora A, **Anderson KS**. Novel T-cell targets for therapeutic vaccine design against HPV 16-associated cancers. Keystone Symposia Conference: Translational Vaccinology for Global Health. Oct 2016
105. Chen M, Andreozzi M, Pockaj B, Barrett MT, Tolgay I, McCullough A, **Anderson KS**. A novel fluorescence in situ hybridization assay to detect 9p24.0 amplification in triple negative breast cancer. San Antonio Breast Cancer Symposium (SABCS) Dec 2016.
106. Chen M, Pockaj B, Andreozzi M, Barrett MT, Tolgay I, McCullough A, Krishna S, **Anderson KS**. JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer. San Antonio Breast Cancer Symposium (SABCS) Dec 2016
107. Chen M, Andreozzi M, Pockaj B, Barrett MT, and **Anderson KS**. A novel fluorescence in situ hybridization assay to detect 9p24.1 amplification in triple negative breast cancer. San Antonio Breast Cancer Symposium (SABCS) Dec 2016
108. Gawryletz CD, **Anderson KS**, Northfelt DW, Kosiorek HE, Linnaus ME, Ocal IT, McCullough AE, Pockaj BA, Barrett MT. Homologous recombination deficiency in PD-L1, PD-L2, Jak2 (PDJ) amplified triple negative breast carcinoma. San Antonio Breast Cancer Symposium (SABCS) Dec 2016
109. Cunningham GT, Race C, Kwon L, Inan H, Kesiraju S, **Anderson KS**, Demirci U, Zangar R. Development of an automated test for an oropharyngeal cancer biomarker in blood using photonic crystal enhanced fluorescence. NIH Innovative Molecular Analysis Technologies (IMAT) Program PI Meeting, Bethesda, MD. Dec 2016
110. Krishna S, Parikh F, Ulrich P, Clark A, Kim-Schulze S, Posner M, Sikora A, **Anderson KS**. Novel T-cell targets for HPV16-associated oropharyngeal cancer immune therapy. AACR April 2017
111. R Ferdosi S, Loo JY, Grewal H, Eaton S, Park J, Yang S, LaBaer J, **Anderson KS**. Synthetic lethal targeting of p53 mutant cells with prenylation inhibitors. AACR April 2017
112. Ewaisha R, Meshay I, Resnik J, Bharaj T, **Anderson KS**. Detection of circulating immune biomarkers of cervical disease using proteome arrays. AACR April 2017
113. Sturgis EM, **Anderson KS**. HPV16 serostatus and risk of oropharyngeal carcinoma. AACR April 2017
114. Zhu M, Obahiagbon U, **Anderson KS**, Blain Christen J. Highly Sensitive Fluorescence-based Lateral Flow Platform for Point-of-Care Detection of Biomarkers in Plasma. IEEE-NIH 2017 Special Topics Conference on Healthcare Innovations and Point-of-Care Technologies.
115. Knappenberger M, Krishna S, Fuhman K, Tan C, Hinerfeld D, Rosenbloom A, and **Anderson KS**. Deep immunoprofiling of rare T-cell populations from clinical samples. SITC Nov 2017
116. Narang P, Chen M, Sharma AA, **Anderson KS**, Wilson Sayres MA. The neo-epitope landscape of breast cancer: implications for immunotherapy. SABCS Dec 2017
117. Hilal T, Mi L, **Anderson KS**, Pockaj B, Gray R, Dixon LE, Martinez ED, Singh CG, Northfelt DW. Change in 21-Gene Recurrence Score (RS) (Oncotype DX) after Exposure to Neoadjuvant Endocrine Therapy. ASCO. Submitted 2018
118. **Anderson KS**. Downregulation of Antigen Processing is Associated with High Neopeptide Burden in Triple Negative Breast Cancer. Surgical Society of Oncology, Chicago, IL. Apr 2018.
119. M Chen, P Yuvaraj, AA Sharma, P Narang, MAW Sayres, **KS Anderson**. Abstract P4-06-04: Targeting neo-epitopes from PIK3CA and p53 mutations for immunotherapy of breast cancer. Cancer Research 79 (4 Supplement), P4-06-04-P4-06-04
120. BR McDonald, T Contente-Cuomo, S-J Sammut, B Ernst, A Odenheimer-Bergman, N Perdignes, S-F Chin, M Farooq, PA Cronin, **KS Anderson**, H Kosiorek, D Northfelt, A McCullough, B Patel, C Caldas, B Pockaj and M Murtaza. Abstract P4-01-21: Multiplexed targeted digital sequencing of circulating tumor DNA to detect minimal residual disease in early and locally advanced breast cancer. Cancer Research 79 (4 Supplement), P4-01-21-P4-01-21. 2019ed
121. A Afsari, L Koslosky, L Ricks-Santi, **K Anderson**, M Barrett, Y Kanaan. 9p24. 1 Amplification Encoding JAK2, PDL1, and PDL2 in Treatment Naive Triple Negative Breast Cancer in African American Females. LABORATORY INVESTIGATION 100 (SUPPL 1), 97-98. 2020

122. SF Ensign, E Yancey, **K Anderson**, M Mrugala. Safety and Feasibility of Intrathecal Pembrolizumab Infusion in Refractory Triple Negative Breast Cancer with Leptomeningeal Disease (2946). *Neurology* 96 (15 Supplement). 2021
123. Bhavika K. Patel, Victor Pizzitola, Donald Northfelt, **Karen Anderson**, Marina Giurescu, Gina Mazza, Roxanne Lorans, William Eversman, Richard Sharpe, Juliana Kling, Denise Millstine, Ernst Brenda, Patricia Cronin, Heidi Apsey, Jennifer Palmieri, Barbara Pockaj and Michele Halyard. Abstract PS2-41: Supplemental contrast enhanced mammography screening of women with elevated risk of breast cancer. *Cancer Research* 81 (4 Supplement), PS2-41-PS2-41. 2021
124. Molly Carnahan, Barbara Pockaj, Victor Pizzitola, Marina Giurescu, Roxanne Lorans, William Eversman, Richard Sharpe, Patricia Cronin, Donald Northfelt, **Karen Anderson**, Brenda Ernst and Bhavika Patel. Abstract PS3-23: Experience of contrast-enhanced mammography in patients with breast augmentation surgery. *Cancer Research* 81 (4 Supplement), PS3-23-PS3-23. 2021